| 证券代码 | ABLX.O |
| 证券名称 | Ablynx NV ADR |
| 证券类型 | 美国存托凭证 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2017-10-25 |
| 首发价格(元) | 17.5 USD |
| 首发数量(股) | 11430000 |
| 首发募资额(元) | 200,025,000.00 USD |
| 首发主承销商 | Merrill Lynch, Pierce, Fenner & Smith Incorporated,J.P. Morgan S |
| 货币单位 | EUR |
| 公司名称 | Ablynx NV |
| 注册地址 | 比利时 |
| 办公地址 | Technolgiepark 21, Ghent/Zwijnaarde, Belgium |
| 成立日期 | 2001-07-04 |
| 董事会主席 | Russell G. Greig |
| 公司属地 | Belgium 比利时 |
| 公司网址 | www.ablynx.com |
| 电话 | +32 9262-0000 |
| 传真 | +32 9262-0001 |
| 公司简介 | Ablynx NV is a late-stage clinical biopharmaceutical company utilizing its proprietary Nanobody platform to develop treatments for a broad range of therapeutic indications with an unmet medical need. It believes that Nanobodies represent a leading next generation protein therapeutic technology. It has more than 45 proprietary and partnered Nanobody programs across a range of therapeutic indications including: hematology, inflammation, infectious disease, autoimmune disease, oncology and immuno-oncology. It employs a hybrid business model whereby it pursues its wholly owned programs through to commercialization or key value inflection points while also working with pharmaceutical partners on programs in areas where they bring specific disease expertise and resources. Its lead, wholly owned product candidate, caplacizumab, for the treatment of acquired thrombotic thrombocytopenic purpura, or aTTP, is currently undergoing regulatory review in Europe, and it recently announced positive top line results from a Phase III trial with caplacizumab in October 2017. Submission of a Biologics License Application for caplacizumab in the United States is planned in the first half of 2018 and it received Fast Track Designation from the FDA for caplacizumab in July 2017. Its wholly owned and partnered product pipeline includes three other Nanobody-based product candidates at the Phase II stage of development and four at the Phase I stage of development, and it and its partners are currently planning to initiate Phase I trials for multiple other product candidates over the next few years. |